Open Menu Close Menu Open Search Close Search Open Directory Close Directory

Comparing two drugs to treat dogs with protein-losing nephropathy (PLN)

The pharmacokinetics and efficacy of telmisartan when compared to benazepril in dogs with protein-losing nephropathy

Status: Recruiting

Species: Dog

Veterinary Speciality: Internal Medicine

Description

To determine if telmisartan, a medication used to reduce protein loss through the kidneys, is broken down and processed differently in dogs with kidney disease compared to healthy dogs.

To compare the ability of telmisartan to control protein loss through the kidneys in dogs with protein-losing kidney disease (protein-losing nephropathy, or PLN) with benazepril, one of the medications in the class of medications (angiotensin-converting enzyme inhibitors) that is currently standard therapy for this disease.

We hypothesize that the processing of telmisartan in dogs with PLN will be altered compared to the patterns previously established in healthy dogs, and that telmisartan will be equally or more effective than benazepril at treating PLN.

This study serves to evaluate telmisartan, a medication commonly used in human medicine, for its role in helping to treat protein-losing nephropathy, a potentially devastating disease in dogs.  If successful, this may open a new option for treatment of dogs with PLN who don’t respond to standard therapies, such as benazepril.  In addition, the pharmacokinetics of telmisartan (or any angiotensin-receptor blocker) in dogs with PLN has not been previously evaluated.

Inclusion Criteria

Dogs who have been diagnosed with protein-losing nephropathy (as defined by having a urine protein:creatinine ratio >2.0 with no evidence of non-renal causes of proteinuria).

Client Benefits

The direct benefit from this study for your dog is that he or she will receive one of two promising therapies for protein-losing kidney disease with close monitoring of his or her response to therapy.  The direct benefit to you is that the costs of either medication (benazepril or losartan) will be covered for the duration of the study (6 months).  You will be responsible for the costs of the preliminary diagnostic tests (including ultrasound) and the costs of the recheck appointments and urine and blood testing at these rechecks.

Contact Info

For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

Print Friendly, PDF & Email